Arcadia Biosciences Stock Earnings Reports
Arcadia Biosciences Earnings Calls
Release date | May 08, 2025 |
EPS estimate | -$0.98 |
EPS actual | $1.90 |
EPS Surprise | 293.88% |
Revenue estimate | 1.3M |
Revenue actual | 1.2M |
Revenue Surprise | -7.69% |
Release date | Mar 20, 2025 |
EPS estimate | -$0.89 |
EPS actual | -$2.48 |
EPS Surprise | -178.65% |
Revenue estimate | 1.15M |
Revenue actual | 1.216M |
Revenue Surprise | 5.74% |
Release date | Nov 12, 2024 |
EPS estimate | -$0.770 |
EPS actual | -$0.87 |
EPS Surprise | -12.99% |
Revenue estimate | 1.15M |
Revenue actual | 1.537M |
Revenue Surprise | 33.65% |
Release date | Aug 13, 2024 |
EPS estimate | $1.55 |
EPS actual | $0.780 |
EPS Surprise | -49.68% |
Revenue estimate | 920K |
Revenue actual | 1.306M |
Revenue Surprise | 41.96% |
Last 4 Quarters for Arcadia Biosciences
Below you can see how RKDA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Release date | Aug 13, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $2.99 |
EPS estimate | $1.55 |
EPS actual | $0.780 |
EPS surprise | -49.68% |
Date | Price |
---|---|
Aug 07, 2024 | $2.62 |
Aug 08, 2024 | $2.66 |
Aug 09, 2024 | $2.66 |
Aug 12, 2024 | $2.92 |
Aug 13, 2024 | $2.99 |
Aug 14, 2024 | $2.66 |
Aug 15, 2024 | $2.77 |
Aug 16, 2024 | $2.65 |
Aug 19, 2024 | $2.71 |
4 days before | 14.12% |
4 days after | -9.36% |
On release day | -11.04% |
Change in period | 3.44% |
Release date | Nov 12, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $4.24 |
EPS estimate | -$0.770 |
EPS actual | -$0.87 |
EPS surprise | -12.99% |
Date | Price |
---|---|
Nov 06, 2024 | $4.16 |
Nov 07, 2024 | $4.08 |
Nov 08, 2024 | $4.05 |
Nov 11, 2024 | $4.24 |
Nov 12, 2024 | $4.24 |
Nov 13, 2024 | $4.19 |
Nov 14, 2024 | $3.86 |
Nov 15, 2024 | $2.90 |
Nov 18, 2024 | $2.84 |
4 days before | 1.92% |
4 days after | -33.02% |
On release day | -1.18% |
Change in period | -31.73% |
Release date | Mar 20, 2025 |
Fiscal end date | Dec 31, 2024 |
Price on release | $3.30 |
EPS estimate | -$0.89 |
EPS actual | -$2.48 |
EPS surprise | -178.65% |
Date | Price |
---|---|
Mar 14, 2025 | $3.23 |
Mar 17, 2025 | $3.23 |
Mar 18, 2025 | $3.30 |
Mar 19, 2025 | $3.44 |
Mar 20, 2025 | $3.30 |
Mar 21, 2025 | $3.15 |
Mar 24, 2025 | $3.14 |
Mar 25, 2025 | $3.43 |
Mar 26, 2025 | $3.31 |
4 days before | 2.17% |
4 days after | 0.167% |
On release day | -4.55% |
Change in period | 2.34% |
Release date | May 08, 2025 |
Fiscal end date | Mar 31, 2025 |
Price on release | $4.29 |
EPS estimate | -$0.98 |
EPS actual | $1.90 |
EPS surprise | 293.88% |
Date | Price |
---|---|
May 02, 2025 | $3.52 |
May 05, 2025 | $3.87 |
May 06, 2025 | $4.39 |
May 07, 2025 | $4.30 |
May 08, 2025 | $4.29 |
May 09, 2025 | $3.88 |
May 12, 2025 | $3.98 |
May 13, 2025 | $4.12 |
May 14, 2025 | $4.16 |
4 days before | 21.88% |
4 days after | -3.03% |
On release day | -9.58% |
Change in period | 18.18% |
Arcadia Biosciences Earnings Call Transcript Summary of Q1 2025
Summary of Key Points from Arcadia Biosciences Q1 2025 Earnings Call for Investors
Financial Performance:
- Revenue Growth: Arcadia reported total revenues of approximately $1.2 million, a 22% increase YoY. Notably, Zola coconut water revenues surged by 90% compared to the previous year, primarily due to expanded distribution (70% increase).
- Gross Margin: The gross margin for Q1 was reported at 43%, down from 52% in Q1 2024, attributed to the transition to a single product line (Zola).
- Operating Expenses: Operating expenses decreased by 16% YoY, despite incurring nearly $500,000 in transaction-related fees during the quarter.
Product Performance and Strategy:
- Zola Coconut Water: Continued strong performance, with positive consumer feedback and growth outpacing the overall coconut water category (Zola growth at 76% vs. 24% for the category).
- New Product Development: Zola is set to launch a new product line (including flavors like lime and pineapple) in early 2026, with an existing appealing pipeline for innovation.
- Inventory Management: Inventory levels are well-managed, with a refilling strategy in place ahead of the peak beverage season, minimizing tariffs' impacts on Q2.
Legacy Business Exit and Intellectual Property Monetization:
- Exit from Legacy AgTech: Successfully executed a transaction with BioSeries; regained rights to certain soy patents and eliminated $1 million in contingent liabilities from its balance sheet through this. Expect to finalize exiting the legacy AgTech business soon.
- Remaining Patent: One tomato patent remains under license; potential commercialization efforts are ongoing, but not directly beneficial for Arcadia.
Pending Business Combination:
- Roosevelt Resources Merger: The anticipated merger with Roosevelt Resources is progressing, with a target completion around mid-August 2025. The revised equity ratio (90-10) aims to provide greater ownership certainty for Arcadia stockholders.
Cash Position and Future Outlook:
- Cash and Receivables: The company's cash balance at the end of Q1 was $3.2 million, down from $4.2 million at the start of the year. Expected cash inflow from a receivable of approximately $2.5 million scheduled for Q2.
- Long-term View: The management expresses optimism for continued growth driven by Zola's expansion, upcoming new product launches, and the streamlined focus on core operations post-merger.
Conclusion
Arcadia Biosciences is experiencing strong growth in its Zola brand, successfully reducing operational costs, and actively managing its transition from legacy businesses, all of which position the company favorably for future performance and shareholder value enhancement.